Cross Country Healthcare price target lowered to $32 from $40 at Jefferies

Jefferies lowered the firm’s price target on Cross Country Healthcare to $32 from $40 and keeps a Buy rating on the shares. The firm has “heard investor skepticism” on Cross Country due to headwinds in temp nurse staffing and thinks increasing attrition rates in MSP contracts “present a notable headwind.” However, the firm thinks earning expectations for the second half and 2024 “have now appropriately adjusted down,” the analyst added.